, Health Personnel/statistics & numerical data , COVID-19 Vaccines/administration & dosage Overall, the findings of the present study highlight two key aspects of the vaccination programs: First, the need for prospective immunosurveillance studies in order to estimate the duration of immunity, and second, the need to identify those individuals who are at a greater risk of developing low IgG titers in order to evaluate the need for a third dose of the vaccine. The present study demonstrated that the immune response after receiving the BNT162b2 COVID19 mRNA vaccine is dependent on various modifiable and nonmodifiable factors. Moreover, the six most prevalent adverse effects were pain at the injection site (72.1%), generalized fatigue (40.5%), malaise (36.3%), myalgia (31,0%), headache (25.8%) and dizziness/weakness (21.6%). An older age was also associated with lower antibody titers (P<0.001). Females had higher titers than males (4.44☒.70 and 3.89 ☒.84, respectively P=0.007), while nonsmokers had higher titers than smokers (4.48☒.79 and 3.80☒.64, respectively P=0.003). SARSCoV2 IgG titers had an overall mean value of 4.23☒.76. Blood sampling was performed at a mean period of 69.0☒3.5 days following the second dose of the vaccine. For this purpose, blood samples from 517 individuals were obtained and analysed.
Moreover, common sideeffects and factors associated with IgG titers were identified.
#After effects of covid pneumonia full
The present study aimed to quantify the immune response following full vaccination with the BNT162b2 coronavirus disease 2019 (COVID19) mRNA vaccine by measuring the levels of immunoglobulin G (IgG) titers in healthcare professionals.
However, almost 8 months following the initiation of the European vaccination programme, the need for prospective monitoring of the vaccineinduced immune response, its determinants and related sideeffects remains a priority. Soon after the beginning of the severe acute respiratory syndrome coronavirus 2 (SARSCoV2) pandemic in December, 2019, numerous research teams, assisted by vast capital investments, achieved vaccine development in a fraction of time.